Replies to post #545485 on NorthWest Biotherapeutics Inc (NWBO)

[dr_lowenstein]

Unlikely as they are not pivotalp3 trials . The keytruda is p1

[SkyLimit2022]

Thanks for the reply—I just thought of something! Liau will be presenting analysis of the ICLC murcidencel data soon—keep an eye out for the date and venue! I believe she said that it would be at an academic conference.

The ICLC trial is a long-running study with long-term survivors and internal placebo controls, so you might enjoy that one.

For me, all the trials are relevant for different reasons and I like to consider the full picture of this novel cell-based technology. You can never have too much data or too much supporting evidence of safety and efficacy!

Thanks again—your posts have provided an underscore of the fact that there is more than one study, and you have provided an opportunity for us to consider other information with regard to controls and clinical data.

Three murcidencel studies producing significant clinical survival data!

1.
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847


2.


3.

[exwannabe]

All the murcidencel studies have produced astonishing data, but pick whichever one you like based on the controls if that’s your concern. External or internal—murcidencel has trials for both types!

There were thousands of posts here with numerous "models" showing how the P3 had clearly been stat sig on PFS and OS.

The PFS win was based on how long it took to have sufficient number of events. So it was not psPD that screwed all those models. It was bad math.

As far as the two combo trials, all we have seen is some limited very early data. One trial had mixed GBM and AA so nobody knows what the data is. The other had so few patients the P value was 0.372.